• Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients. Moderna’s vaccine, based on its messenger RNA technology, is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer*, in a phase 2 trial. The companies expect to report data in the fourth quarter of this year.

This post is for subscribers only

Sign up now to read the post and get access to the full library of posts for subscribers only.

Sign up now Already have an account? Sign in